nmd

NMDI14 is a highly specific, small-molecule, non-competitive inhibitor of the nonsense-mediated RNA decay (NMD) pathway with an IC₅₀ value of 1.8 μM. NMDI14 can be used for studying NMD pathway function, PTC-related genetic disorders, and tumor research.

NMD670 is an orally active, partial inhibitor of the skeletal muscle-specific chloride channel ClC-1. It enhances muscle excitability and neuromuscular transmission, restoring muscle function and mobility. NMD670 has a favorable safety profile and improves muscle function in rats, particularly in an MG rat model [1].

ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.

N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA (N-Methyl-D-aspartic acid) receptor subtype of glutamate receptors.

NMDA-IN-1 is a potent and NR2B-selective antagonist of NMDA, with an NMDA Ki of 0.85 nM and an NR2B Ca2+ influx IC50 of 9.7 nM.

(R)-DNMDP is a potent and selective cancer cytotoxic agent that directly binds PDE3A and has an EC50 500-fold lower than that of (S)-DNMDP against HeLa.

DNMDP is a potent and selective PDE3A inhibitor with anticancer activity. It binds to PDE3A, promoting its interaction with Schlafen 12 (SLFN12).

NMDAR antagonist 2 (compound 3I) is a blood-brain barrier permeable antagonist of NMDA receptors, exhibiting IC50 values of 4.42 μM and 214.75 μM at membrane potentials of -60 mV and 40 mV, respectively, for hGluN1/hGluN2A. This compound has been shown to mitigate hippocampal damage.

NMDA agonist 1 (compound 42d) is a potent NMDA agonist with a Ki value of 96 nM. It acts as a partial agonist of the GluN1/GluN2B complex, exhibiting an EC50 value of 78 nM.

NMDA agonist 2 (compound 8d) effectively inhibits NMDA receptors, exhibiting an EC50 of 0.034 μM for GluN1/2C. It plays a significant role in neurological and psychiatric disorders.

NMDAR antagonist 5 (Compound A17) is a multi-target antagonist that acts on NMDAR and monoamine transporters (SERT, DAT, and NET). It demonstrates strong NMDAR antagonistic efficacy (IC50= 0.3 μM) and effective activity on monoamine transporters (SERT IC50= 1.1 μM, DAT IC50= 0.7 μM, NET IC50= 2.7 μM). NMDAR antagonist 5 exhibits high safety with low toxicity (hepatic and renal toxicity IC50> 100 μM; cardiac toxicity IC50= 24.5 μM). It has antidepressant properties and is useful for depression research.

GluN2B-NMDAR antagonist-2 (compound S-58) is an effective and selective NMDAR-GluN2B antagonist that can cross the blood-brain barrier, with an IC50 value of 74.01 nM. It exhibits mild cytotoxicity and reduces both infarct size and neurological deficit scores in the brain, indicating its potential for stroke research.

NMDA receptor modulator9 is an orally active positive allosteric modulator (PAM) of the NMDA receptor. It enhances the activity of the GluN2A receptors. In a chronic restraint stress (CRS) induced depression mouse model, NMDA receptor modulator9 exhibits significant antidepressant-like effects. It is used for research on depression.

NMDA caged with the photosensitive 4-methoxy-7-nitroindolinyl group

PMPA (NMDA antagonist) is a Competitive NMDA receptor antagonist.

ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.

ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.

ENMD-1068 HBr is a novel Proteinase-Activated Receptor 2 antagonist.

ENMD-1068 HCl (ENMD 1068) is a PAR-2 antagonist. ENMD-1068 HCl inhibits the development of endometriosis in a mouse model.

NMDA receptor antagonist 2 is a highly potent and orally active NR2B subtype-selective antagonist of the N-methyl-D-aspartate (NMDA) receptor, with an IC50 of 1.0 nM and a Ki value of 0.88 nM. This compound is valuable in scientific investigations of neuropathic pain and Parkinson's disease.

NMDAR antagonist 1 is an orally active, NR2B-selective NMDAR antagonist.

NMDA receptor antagonist 4 (IIc) is an uncompetitive, voltage-dependent, orally active NMDAR blocker with an IC50 of 1.93 μM. It shows positive predicted blood-brain-barrier (BBB) permeability and can be used in Alzheimer's disease research[1].

NMDA-IN-2 (compound 6b) is a Procaine derivative that is an inhibitor of NMDA receptor 2B subtype [1].

NMDA receptor modulator 2 (Compound 1) is a potent NMDA receptor modulator suitable for neurological disorder research [1].